MORRISVILLE, N.C., Oct 27, 2011 (GlobeNewswire via COMTEX) --
Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX:OXBT) today announced that the SIX Swiss Stock Exchange has approved the application filed by the company on September 30, 2011, to remove the company's shares from trading on the SIX exchange. This application was filed after the Company's Board of Directors determined that the cost of maintaining the SIX listing was not justified in light of the low trading volume of the Company's shares over the past 12 months. The last day of trading for the company's common stock on the SIX will be January 30, 2012.
Shares will continue to trade on the NASDAQ OMX under the symbol OXBT.
About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is developing topical and intravenous medical products that deliver oxygen to tissues in the body. Currently, the company is focused on developing therapeutics for wound healing, dermatologic indications, traumatic brain injury, and decompression sickness. In addition, the Company markets and sells its DERMACYTE® line of oxygen-rich skin care products in the United States, Europe and Mexico. More information is available at oxybiomed.com, or DermacyteUS.com.
